AstraZeneca (AZ) has shared “unprecedented” overall survival (OS) results from a late-stage study of Imfinzi (durvalumab) ...

GSK’s “ultra-long-acting” biologic depemokimab has demonstrated a significant reduction in severe asthma exacerbations over ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Regeneron Pharmaceuticals has shared positive five-years results from a late-stage study of Libtayo (cemiplimab) in advanced lung cancer. The phase 3 EMPOWER-Lung 1 trial compared the monoclonal ...

Sanofi’s investigational BTK inhibitor tolebrutinib has demonstrated promising results in a phase 3 study of patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), which the ...

Avalere Health has announced the appointment of Corrina Safeio as its new president, global marketing and executive vice president, corporate communications. In this role, Safeio will oversee the ...

Sanofi and Regeneron’s Dupixent (dupilumab) has demonstrated significant improvements in itch and hives for patients with chronic spontaneous urticaria (CSU), according to late-stage results shared by ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo’s investigational antibody-drug conjugate (ADC) ifinatamab deruxtecan has demonstrated promising results in a mid-stage lung ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

Syneos Health Communications and Precision AQ led the agency list, while Novartis, Roche and Takeda shared the top client spot Over the course of 15 years, the PM Society Digital Awards have become a ...

Johnson & Johnson (J&J) has shared positive longer-term data for its chemotherapy-free combination, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib), in adults with non-small cell lung cancer ...